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Abstract
Background: Proliferation and migration of endothelial progenitor cells (EPCs) play important roles in restoring
vascular injuries. β2 adrenergic receptors (β2ARs) are widely expressed in many tissues and have a beneficial impact
on EPCs regulating neoangiogenesis. The aim of the present study was to determine the effect of overexpressing
β2ARs in infused peripheral blood (PB)-derived EPCs on the re-endothelialization in injured vessels.
Methods: Induction of endothelial injury was performed in male nude mice that were subjected to wire-mediated
injury to the carotid artery. Human PB-derived EPCs were transfected with an adenovirus serotype 5 vector expressing
β2AR (Ad5/β2AR-EPCs) and were examined 48 h later. β2AR gene expression in EPCs was detected by real-time
polymerase chain reaction and Western blot analysis. In vitro, the proliferation, migration, adhesion, and nitric oxide
production of Ad5/β2AR-EPCs were measured. Meanwhile, phosphorylated Akt and endothelial nitric oxide synthase
(eNOS), which are downstream of β2AR signaling, were also elevated. In an in vivo study, CM-DiI-labeled EPCs were
injected intravenously into mice subjected to carotid injury. After 3 days, cells recruited to the injury sites were
detected by fluorescent microscopy, and the re-endothelialization was assessed by Evans blue dye.
Results: In vitro, β2AR overexpression augmented EPC proliferation, migration, and nitric oxide production and
enhanced EPC adhesion to endothelial cell monolayers. In vivo, when cell tracking was used, the number of recruited
CM-DiI-labeled EPCs was significantly higher in the injured zone in mice transfused with Ad5/β2AR-EPCs compared with
non-transfected EPCs. The degree of re-endothelialization was also higher in the mice transfused with Ad5/β2AR-EPCs
compared with non-transfected EPCs. We also found that the phosphorylation of Akt and eNOS was increased in
Ad5/β2AR-EPCs. Preincubation with β2AR inhibitor (ICI118,551), Akt inhibitor (ly294002), or eNOS inhibitor (L-NAME)
significantly attenuated the enhanced in vitro function and in vivo re-endothelialization capacity of EPCs induced by
β2AR overexpression.
Conclusions: The present study demonstrates that β2AR overexpression enhances EPC functions in vitro and enhances
the vascular repair abilities of EPCs in vivo via the β2AR/Akt/eNOS pathway. Upregulation of β2AR gene expression
through gene transfer may be a novel therapeutic target for endothelial repair.
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Background
Coronary atherosclerotic heart diseases are the major
cause of mortality worldwide in cardiovascular disease
(CVD), yet current therapies only delay disease progres-
sion and improve lifestyle without addressing the funda-
mental problem of tissue loss. Several studies have shown
that endothelial dysfunction is an early marker of athero-
sclerosis, and the activation of inflammatory processes
and abnormalities in vascular homeostasis have been sug-
gested to contribute to the development of atherosclerotic
vascular disease [1]. Accumulating evidence indicates that
the balance between endothelial injury and repair is a key
component of atherosclerosis [2], and maintaining endo-
thelial integrity is crucially important to preventing the
initiation and development of atherosclerosis, coronary
heart disease, and postangioplasty restenosis [3]. Thus, ac-
celerated re-endothelialization might prevent the early
stages of atherosclerosis and restenosis after angioplasty.
Endothelial progenitor cells (EPCs) mobilized from bone
marrow into the peripheral blood (PB) have been shown
to play an important role for vascular regeneration, endo-
thelial repair, and replacement of dysfunctional endothe-
lium by incorporating into the site of vessel injury,
differentiating into endothelial cells (ECs), and releasing
paracrine factors [4, 5]. Transplantation of EPCs is cur-
rently under intensive investigation in animal models and
clinical research and have become a major focus of CVD
treatment to accelerate re-endothelialization [6]. However,
the beneficial effects of this practice have not been ob-
served in patients with coronary artery disease, because
the reparative capacity of EPCs appears to be limited by
their poor survival environment [7]. Therefore, attempts
to improve the function of transplanted EPCs with gene
modifications may facilitate the repair of damaged endo-
thelia and accelerate re-endothelialization.
Various molecules may be involved in the processes by
which EPCs home to and restore damaged endothelium,
such as nitric oxide (NO), stromal cell-derived factor 1a
(SDF-1a), and vascular endothelial growth factor (VEGF).
It is widely accepted that β-adrenoceptors exist on ECs
and contribute to the regulation of vasomotor tone.
Moreover, it is the β2 adrenergic receptor (β2AR), the
most abundant βAR in the vasculature, that mediates the
NO involved in relaxing vascular tone [8]. β2ARs, G
protein-coupled receptors, are activated by adrenergic cat-
echolamine to promote a series of intracellular signal
transduction pathways that lead to multiple cell-specific
responses [9]. It has been demonstrated that β2ARs are
strongly expressed on EPCs and also mediate the homing
and neovascularization capacity of EPCs to areas of ische-
mia [9]. Accordingly, the β2AR gene may be a valuable
molecular target for gene therapies that use EPCs. How-
ever, β2ARs have not previously been shown to accelerate
vascular repair via re-endothelialization mediated by
EPCs. Thus, we sought to determine whether β2AR gene
transfer mediates the functional properties of EPCs during
vascular injury.
In this study, we tested the therapeutic potential of
β2AR gene transfer in EPCs by infusing transfected cells
into nude mice after we induced an endothelial denuda-
tion injury. We also investigated the β2AR-mediated Akt/
endothelial nitric oxide synthase/NO (Akt/eNOS/NO) sig-
naling pathway that is related to both in vitro and in vivo
biology of EPCs. These data demonstrate that the β2AR
has an important role in EPC migration at the vascular in-
jury site, and upregulating β2AR expression is a potential




The experimental research on humans in this study was
performed in compliance with the Helsinki Declaration.
All recruited patients consented to participate in this trial
and to contribute their trial data for non-commercial pur-
poses. The protocol of this trial was externally reviewed
and approved by an anonymous independent ethical re-
view committee to ensure that there were no serious eth-
ical concerns. The animal procedures in this study
complied with the Animal Care and Use Ethics Commit-
tees of Sun Yat-Sen University.
EPC culture and characterization
EPCs were isolated and cultured according to previously
described methods [10, 11]. Briefly, PB mononuclear cells
(MNCs) were isolated from healthy subjects (males from
25 to 35 years of age) by using Histopaque-1077 density
gradient centrifugation at 400 g for 30 min. The collected
MNCs were washed three times with phosphate-buffered
saline (PBS) (Jingmei Bio Tech Co. Ltd., Shenzhen,
China). After the cells were purified, the MNCs were cul-
tured on fibronectin-coated six-well plates in endothelial
basal medium-2 (EBM-2) (CC-4176; Lonza, Basel,
Switzerland) supplemented with EGM-2 Bullte Kit
(Lonza) and 20 % fetal bovine serum (FBS) (Gibco, now
part of Thermo Fisher Scientific, Waltham, MA, USA).
After 4 days in culture, the non-adherent cells were aban-
doned. Adherent cells were cultured for 7 days and then
were used for the following experiments.
EPCs were defined as cells that were dually positive
when stained by using 1,1′-dioctadecyl-3,3,3′,3′-tetra-
methylindocarbocyanine (DiI)-acetylated low-density
lipoprotein (ac-LDL) (20 μg/ml; Invitrogen, Carlsbad,
CA, USA) and fluorescein isothiocyanate (FITC)-labeled
BS-1 lectin (10 μg/ml; Sigma-Aldrich, St. Louis, MO,
USA). Cultured EPCs were incubated with DiI-ac-LDL
for 3 h at 37 °C; the cells then were washed in PBS, fixed
in 4 % (vol/vol) paraformaldehyde (PFA) for 30 min, and
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incubated with FITC-labeled BS-1 lectin for 1 h. The
cells were washed again and then incubated with 4′,6-dia-
midino-2-phenylindole (DAPI), a nuclear counterstain.
Double-positive cells were observed with a fluorescence
microscope (×200 magnification; Olympus, Tokyo, Japan).
Cells demonstrating double-positive fluorescence were
identified as differentiating EPCs.
Flow cytometric analysis
The expression of endothelial marker proteins was ex-
amined in the cultured EPCs by using flow cytometric
analysis with phycoerythrin (PE)-labeled monoclonal
mouse anti-human antibodies recognizing CD31 (BD
Pharmingen, San Diego, CA, USA), von Willebrand fac-
tor (vWF) (BD Pharmingen), kinase-insert domain re-
ceptor (KDR) (R&D Systems, Minneapolis, MN, USA),
and CD14 (BD Pharmingen). To identify the cells that
expressed these surface antigens, the EPCs were incu-
bated for 40 min at 4 °C in a volume of 100 μl of solu-
tion containing an appropriate amount of PE-labeled
antibody or corresponding IgG isotype control. At least
1 × 105 EPCs were acquired by using a flow cytometer
(Beckman-Coulter, Fullerton, CA, USA).
Immunofluorescence
To characterize the expression of EC markers, EPCs
were grown in fibronectin-coated six-well plates, and
immunofluorescence analysis was performed by using
rabbit polyclonal antibody against β2AR (Abcam, Cam-
bridge, MA, USA) and mouse monoclonal antibody
(mAb) against eNOS (Cell Signaling Technology, Bos-
ton, MA, USA). Briefly, the cells were washed in cold
PBS three times and fixed in 4 % PFA for 30 min. Then
the cells were washed again with PBS three times for
5 min each and incubated in 3 % bovine serum albumin
(BSA) in PBS for 1 h. The cells were incubated with pri-
mary antibodies (anti-eNOS, anti-β2AR diluted 1:100
with 3 % BSA in PBS) at room temperature for 1 h. After
the cells were washed three times for 5 min each in PBS
on a shaker, the cells were exposed to goat anti-rabbit
IgG (H + L) (catalog no. A-11011; Life Technologies,
Carlsbad, CA, USA) and goat anti-mouse IgG (H + L)
(catalog no. A-11011; Life Technologies) secondary anti-
bodies for 1 h in the dark. The cells were washed again
and incubated with DAPI to stain the EPC nuclei. Im-
ages were acquired by using a fluorescence microscope
(×200 magnification; Olympus).
EPC gene transfer
An adenovirus sero-type 5 (Ad5) vector expressing the
human β2AR gene (Ad5/β2AR) or enhanced green fluor-
escent protein (Ad5/EGFP) was used for gene delivery
(purchased from GeneChem Company Ltd., Shanghai,
China). To establish the appropriate virus concentration
for adenoviral gene transfer into EPCs, the effectiveness
of different multiplicities of infection (MOIs) was evalu-
ated in accordance with the instructions of the adeno-
virus manufacturer. Briefly, after the EPCs were cultured
for 7 days, they were transduced with Ad5/β2AR and
Ad5/EGFP in serum-free culture medium (MOI of
approximately 500). The viruses were removed, and
the cells were washed with PBS and incubated with
EPC medium for another 48 h before subsequent
experiments.
Real-time polymerase chain reaction and Western blot
analysis
Total cellular RNA was isolated by using TRIzolreagent
(Invitrogen). Double-stranded cDNA was synthesized by
using an M-MLV Reverse Transcriptase cDNA Synthesis
Kit (TaKaRa, Kusatsu, Shiga, Japan). Quantitative poly-
merase chain reaction (PCR) was carried out with Light
Cycler 480 SYBR Green I Master Mix (Roche Diagnos-
tics, Risch-Rotkreuz, Switzerland) in a Light Cycler 480
System. The cycling protocol for the PCR was as follows:
95 °C for 5 min, followed by 45 cycles of 95 °C for 10 s,
60 °C for 10 s, and 72 °C for 20 s. The primers used were
as follows: β2AR: 5′-ATGGTGTGGATTGTGTCAGG-3′
(forward) and 5′-CAGGTCTCATTGGCATAGCA-3′ (re-




EPCs were lysed with cell lysis buffer (Cell Signaling
Technology) in accordance with the instructions of the
manufacturer. Cell lysates were quantified by bicinchoni-
nic acid (BCA) methods in accordance with the instruc-
tions of the manufacturer (Sangon Biotechnology,
Shanghai, China). In total, 50 μg protein was subjected
to SDS-PAGE and then transferred to polyvinylidene
fluoride membranes. The following antibodies were
used: rabbit anti-β2AR antibody (1:1000; Abcam,
Cambridge, MA, USA), Phospho-Akt (Ser473) rabbit
mAb (1:1000; Cell Signaling Technology), Phospho-
eNOS (Ser1177) rabbit mAb (1:1000; Cell Signaling
Technology), eNOS (49G3) rabbit mAb (1:1000; Cell
Signaling Technology), Akt (C67E7) rabbit mAb (1:1000;
Cell Signaling Technology), SDF-1 antibody (1:1000; Cell
Signaling Technology), CXCR4(H-118) (1:1000; Santa
Cruz Biotechnology, Inc., Dallas, TX, USA), and GAPDH
(14C10) rabbit mAb (1:1000; Cell Signaling Technology).
Proteins were visualized with horseradish peroxidase-
conjugated anti-rabbit IgG (1:5000; Cell Signaling Tech-
nology). To detect the effect of stimulation of PB-
derived EPCs with the selective β2AR agonist fenoterol
(FENO) on the phosphorylation of Akt and eNOS, EPCs
were pre-incubated with 10−8 M FENO (Sigma-Aldrich)
for 6 h before proteins were harvested.
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EPC proliferation and NO production
The effect of β2AR gene transfer into EPCs on cell pro-
liferation was assessed by CCK8 (Dojindo Molecular
Technologies, Kumamoto, Japan). EPCs were transduced
with Ad5/β2AR or Ad5/EGFP, or they were not trans-
duced (control). The EPCs were reseeded on 96-well
plates. Briefly, the EPCs were seeded in 96-well plates
(5 × 103 cells per well) in EBM-2 (Lonza, CC-4176) sup-
plemented with 1 % FBS for 24 h. The medium then was
replaced with 100 μl of fresh medium containing 10 μl
of CCK8 solution, and the cells were incubated for an-
other 2 h. The absorbance of each well then was deter-
mined at 450 nm by using an Infinite F200 Multimode
plate reader. We used 0.3 μM ICI118,551 (Sigma-Aldrich),
10 μM LY294002 (Calbiochem, now part of EMD
Millipore, Billerica, MA, USA), and 100 μM L-NAME
(Calbiochem) to inhibit β2AR, Akt, and eNOS, re-
spectively. The EPCs were preincubated with inhibitor
for 30 min before FENO (10−8 M) stimulations.
NO secretion by EPCs was measured as the generation
of nitrite. The cells were cultured with EBM-2 (growth
factor-free) for 48 h after gene transfer. The superna-
tants were assayed to determine the level of NO by using
a NO assay kit by the nitrate reductase method (Nanjing
Jiancheng Institute of Biological Engineering, Nanjing,
China).
In vitro EPC migration assays
EPC migration assays were performed by using a Trans-
well system (Corning Costar, Tewksbury, MA, USA)
with 8-μm polycarbonate filter inserts in 24-well plates.
Briefly, a total of 2 × 104 EPCs were suspended in 250 μl
of EBM-2 medium supplemented with 1 % FBS, and the
cells were incubated in the upper chamber for 30 min
for each group. These groups included the control
group, Ad5/β2AR-EPC group, and Ad5/EGFP-EPC
group, which were not pretreated, and the Ad5/β2AR-
EPC group and Ad5/EGFP-EPC group, which were pre-
treated with ICI118,551, LY294002, and L-NAME. The
lower compartment of the modified Boyden chamber
was placed in a 24-well culture plate in which each well
was filled with 500 μl of EBM-2 supplemented with PBS
or FENO (10−8 M). After the cells were cultured for 6 h,
the cells that had migrated into the lower chamber were
stained with DAPI. The transmigrated cells were ran-
domly counted by an independent investigator who was
blinded to treatments.
In vitro EPC adhesion assays
A monolayer of human umbilical vein endothelial cells
(HUVECs) was prepared 48 h before the assay by plating
2 × 105 cells in each well of a four-well plate. The
HUVECs were pretreated with or without 1 ng/ml
tumor necrosis factor-α (TNF-α) (PeproTech, Rocky
Hill, NJ, USA) for 12 h. Then 1 × 105 CM-DiI (Cell-
Tracker™ CM-DiI, Invitrogen)-labeled EPCs was added to
each well, and the cells were incubated for 3 h at 37 °C.
The non-attached cells were gently removed with PBS,
and the adherent EPCs were fixed in 4 % PFA and ran-
domly counted by an independent investigator who was
blinded to treatments.
Animal model and in vivo re-endothelialization assay
The carotid artery injuries and EPC transplantation were
performed by using previously described methods [12, 13].
Male NRMInu/nu athymic nude mice (The Laboratory
Animal Center of Sun Yat-sen University, Guangzhou,
China) that were 6 to 8 weeks old were injected with hu-
man PB-derived EPCs. The animals were anaesthetized
with ketamine (100 mg/kg intraperitoneally) and xylazine
(5 mg/kg intraperitoneally). The surgeries were performed
by using a stereoscopic microscope. The left carotid artery
was exposed via a midline incision on the ventral side of
the neck. The bifurcation of the carotid artery was located,
and two ligatures were placed around the external carotid
artery, which then was tied off with the distal ligature. An
incision hole was made between the ligatures to introduce
the denudation device. A curved flexible wire (0.35-mm
diameter) was introduced into the common carotid artery
and passed over the lining of artery three times to denude
the endothelium. The wire then was removed, and the ex-
ternal carotid artery was tied off proximal to the incision
hole with the proximal ligature.
EPCs (1 × 106 cells) that had been cultured for 7 days
were resuspended in 100 μl of pre-warmed PBS (37 °C)
and were transplanted 3 h after carotid artery injury via
tail vein injection with a 27-G needle. The same volume
of PBS was injected into placebo mice as a control.
Three days after carotid artery injury, endothelial regen-
eration was evaluated by staining denuded areas with
50 μl of 5 % Evans blue dye via tail vein injection. To
examine the homing of transplanted EPCs to the site of
the injured carotid vessel, labeled EPCs (1 × 106) were
incubated with CM-DiI (Cell Tracker™ CM-DiI; Invitro-
gen) in accordance with the instructions of the manufac-
turer. CM-DiI-labeled EPCs incorporated in the injured
vessels were quantitatively analyzed under a fluorescence
microscope (Olympus BX51).
Statistical analysis
All results are expressed as the mean ± standard error of
the mean. Statistical significance was evaluated by means
of Student’s t test or analysis of variance. A P value of
less than 0.01 was considered to denote statistical signifi-
cance. All statistical analyses used SPSS statistical soft-
ware (SPSS version 13.0; IBM Corporation, Armonk,
NY, USA).
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Results
Characterization of EPCs and endogenous expression of
β2AR on EPCs
Recently, EPCs were classified into two distinct types:
early and late EPCs. Early EPCs appear after 5 to 7 days,
and late EPCs appear after 14 to 21 days [14]. A benefi-
cial effect on vascular repair after injury has been shown
for early EPCs [15]. After 7 days of culture on
fibronectin-coated plates, PB-derived EPCs had a
spindle-shaped morphology. Cellar immunostaining
showed that most of the adherent cells have double-
positive staining for the uptake of DiI-ac-LDL and for
the binding of FITC-lectin, indicating that these cells
possess the functional properties of ECs (Fig. 1a). In
addition, flow cytometric analysis of EC antigens re-
vealed that 40.82 ± 3.98 % of the adherent cells were
positive for CD31, 50.69 ± 4.76 % for vWF, 96.56 ±
8.76 % for VEGF (VEGFR2/KDR), and 55.47 ± 4.75 % for
the monocytic maker CD14 (Fig. 1b). All of these char-
acteristics indicate that the cultured adherent cells were
appropriately identified as EPCs, as previously described
[12, 16]. We performed immunocytochemistry for colo-
calization of β2ARs and the EPC marker eNOS. Fluores-
cence microscopy revealed that β2ARs were found to
localize to the cell membrane of EPCs, and these results
were confirmed by using a positive marker, eNOS, which
is also expressed in EPCs (Fig. 1c). In addition, β2AR ex-
pression on the EPCs did not increase when the cells
were stimulated with the selective β2AR agonist FENO
for 6 or 12 h, as shown in the Western blot analyses.
These results are consistent with the findings of Galasso
et al. (Fig. 1d) [9].
Overexpression of β2AR in transfected EPCs
Adenovirus effectively mediated the transfection of the
β2AR gene into EPCs. To upregulate the β2AR gene in
EPCs, we transduced EPCs by using Ad5/β2AR gene
transfection. At 24 h after transfection, EGFP expression
was detected by fluorescent microscopy, and the trans-
fection efficiency was approximately 80 % (data not
shown). At 48 h after transfection, our results showed
that β2AR mRNA was significantly increased in the
Ad5/β2AR-EPC group compared with the Ad5/EGFP-
EPC group or in controls by using real-time PCR (9.73
± 3.56 versus 0.89 ± 0.65 or 1.00 ± 0.47; P < 0.01). These
results were further confirmed by using Western blot
analysis (0.40 ± 0.03 versus 0.18 ± 0.03 or 0.2 ± 0.01; P <
0.01) (Fig. 2a, b).
β2AR gene transfer in EPCs upregulates cell proliferation,
migration and adhesion; NO production; SDF-1/CXCR4
expression in vitro
We used CCK8 assays to examine whether overexpress-
ing β2AR affected proliferation in EPCs that were
stimulated with FENO. The rate of proliferation was sig-
nificantly higher in the Ad5/β2AR-transduced EPCs than
in the Ad5/EGFP-transduced EPCs or the non-
transduced EPCs (Fig. 3a). We also detected NO produc-
tion by analyzing NO levels in the conditioned media at
48 h after β2AR gene transfer. As shown in Fig. 3b, the
level of NO production was higher in the Ad5/β2AR-
transduced EPCs than in the Ad5/EGFP-transduced
EPCs or the non-transduced EPCs.
In the migration assays, there were no differences in
basal migration capacity among Ad5/β2AR-transduced
EPCs, Ad5/EGFP-transduced EPCs, and non-transduced
EPCs. However, the rate of EPC migration was signifi-
cantly higher in Ad/β2AR-transduced EPCs that were in-
duced by FENO stimulation than in the Ad5/EGFP
transduced EPCs and non-transduced EPCs that were
stimulated by FENO (28.2 ± 4.2 versus 20.2 ± 5.5 or 20.6
± 4.6; P < 0.01) (Fig. 3c-e).
TNF-α can enhance the expression of adhesion mole-
cules in ECs [16]. To determine the function of β2AR in
EPC adhesion, we investigated its role in the adhesion of
EPCs cultured on mature HUVEC monolayers. Similar
to the results of the migration assay, without TNF-α
stimulation, there was no difference in the adhesiveness
of EPCs cultured on HUVECs among the Ad5/β2AR-
transduced, Ad5/EGFP-transduced, and non-transduced
EPC groups. However, when the HUVECs were activated
with TNF-α, the adhesive ability of the Ad5/β2AR-trans-
duced EPCs was greater than the adhesive ability of the
Ad5/EGFP-transduced EPCs and the non-transduced
EPCs (61.2 ± 7.2 versus 27.4 ± 4.1 or 28.6 ± 4.9; P < 0.01)
(Fig. 3d-f ). Therefore, these data suggested that β2AR
mediated the biological function of EPCs in vitro and
that β2AR overexpression would increase the regulatory
capacity of EPCs.
The chemokine stromal-derived factor (SDF-1) and its
unique receptor CXCR4 (SDF-1 and CXCR4 axis) play
an important role invasculogenesis, neovascularization,
and re-endothelialization [17, 18]. SDF-1 and CXCR4
are also involved in the biological functions of EPCs, in-
cluding migration, adhesion, mobilization, and homing.
Interestingly, in our study, Western blot analysis re-
vealed that SDF-1 and CXCR4 levels were significantly
higher at both time points in the cells that were stimu-
lated with FENO than in the control EPCs that were not
stimulated with FENO, and this difference was stronger
in the Ad5/β2AR-transduced EPC group (Fig. 3g). These
results suggest that β2AR stimulation promotes the ex-
pression of members of the SDF-1/CXCR4 axis in EPCs.
β2AR gene transfer increases the re-endothelialization
capacity of EPCs in vivo
The carotid endothelium injury in mice was confirmed
by Evans blue staining (Fig. 4a). To assess the capability
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of transplanted EPCs on endothelium recovery, we
injected PB-derived EPCs into a nude mice model in
which we caused wire-denuded carotid arteries. PBS,
Ad5/β2AR-transduced EPCs, or Ad5/EGFP-transduced
EPCs were injected into nude mice through the tail vein.
Notably, compared with PBS, treatment with non-
transduced EPCs or with Ad5/EGPF-transduced EPCs
substantially increased re-endothelialization of denuded
carotid arteries in nude mice; however, injecting the
Ad5/β2AR-transduced EPCs resulted in a larger re-
endothelialization area in the injured carotid arteries
(82.1 ± 4.2 % versus 44.4 ± 6.5 % or 46.8 ± 4.3 % versus
26.6 ± 7.5 %, n = 5, P < 0.01; Fig. 4b). To determine
whether labeled EPCs were able to home and incorpor-
ate into the sites of vascular endothelium injury, each
mice was injected with 1 × 106 CM-DiI-labeled EPCs
after carotid artery injury. DiI-labeled EPCs were identi-
fied as red fluorescent cells. Data showed that there were
more homing EPCs in the Ad5/β2AR-transduced EPC
group than in the Ad5/EGFP-transduced EPC group that
incorporated into the FITC-lectin-positive endothelial
layer (Fig. 4c, d).
Fig. 1 Characterization of EPCs and endogenous expression of β2AR on EPCs. a Representative photographs of EPCs at 7 days that were labeled
with DAPI (blue), FITC-labeled BS-1 lectin (green), and DiI-acLDL uptake (red). Double-labeled cells were identified as EPCs (yellow) (×200). b Cells
were tested for the ability to express the endothelial markers CD31, vWF, KDR, and CD14 by using flow cytometry analysis (IgG isotype control is
shown in blue, n = 4 per group). c The expression of β2AR protein was confirmed on EPC surfaces by using immunofluorescence. The expression
of β2AR (green) and eNOS (red) and colocalization of both receptors on EPCs (yellow) are shown. d Representative photographs and quantitative
analyses of the β2AR protein expressed on EPCs after stimulation with FENO. The results show that β2AR expression was not changed in the EPCs
that were stimulated by using FENO. DAPI 4‘,6-diamidino-2-phenylindole, DiI-ac-LDL DiI-labeled acetylated low-density lipoprotein, eNOS endothelial
nitric oxide synthase, EPC endothelial progenitor cell, FENO fenoterol, FITC fluorescein isothiocyanate, KDR kinase-insert domain receptor, vWF von
Willebrand factor, β2AR β2 adrenergic receptor
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The β2AR/Akt/eNOS pathway improves EPC function in
vitro and the endothelial repair capacity of EPCs in vivo
The activations of Akt and eNOS are both important to
determining the number and function of active EPCs.
The activation of βARs in cardiac progenitor cells
(CPCs) was previously shown to promote the prolifera-
tion and survival of CPCs and to be associated with the
increased phosphorylation of Akt and eNOS. Therefore,
we examined whether the β2AR/Akt/eNOS signaling
pathway plays an important role in the proliferation, NO
production, migration, and adhesion of EPCs. We used
inhibitors, including ICI118,551 (a selective inhibitor of
β2AR), LY294002 (an Akt inhibitor), and L-NAME (an
eNOS inhibitor), to inhibit the activation of the β2AR/
Akt/eNOS signaling pathway.
Following stimulation with FENO (10−8 M) for 6 h,
the phosphorylation levels of Akt and eNOS were en-
hanced in the Ad5/β2AR-transduced EPCs compared
with those in the Ad5/EGFP-transduced EPCs and in
the non-transduced EPCs. Furthermore, the increases in
Akt and eNOS phosphorylation that were observed in
the Ad5/β2AR-transduced EPCs were inhibited by pre-
incubation for 1 h with 0.3 μ M of ICI118,551, 10 μM
LY294002 or 100 μM L-NAME (Fig. 5a, b). Interestingly,
we also found that β2AR overexpression-mediated ef-
fects on proliferation, NO production, migration, and
adhesion were all significantly inhibited by pre-
treatment with ICI118,151, LY294002, and L-NAME
(Fig. 5c-f). These results indicate that the β2AR/Akt/
eNOS signaling pathway is at least partially responsible
for the function of EPCs in vitro. We also investigated
whether the β2AR/Akt/eNOS signaling pathway is asso-
ciated with the re-endothelialization capacity of EPCs in
vivo. In agreement with the in vitro results, pre-
treatment with inhibitors of β2AR, Akt, and eNOS at-
tenuated the enhanced re-endothelialization in the mice
that were transplanted with Ad5/β2AR-transduced EPCs
(Fig. 5g).
Discussion
The present study demonstrates that β2AR expression
on EPCs is involved in the restoration of damaged endo-
thelium. Ad5/β2AR gene transfer treatment enhanced
β2AR expression in EPCs and increased the capacity of
EPCs to migrate, adhere, proliferate, and secrete NO in
vitro and the re-endothelialization capacity of EPCs in
vivo. Moreover, the increase in re-endothelialization cap-
acity of EPCs is closely correlated with upregulation of
the β2AR/Akt/eNOS pathway. Our present study is the
first to demonstrate that β2ARs play a crucial role in
regulating the vascular endothelial repair function of
EPCs. At the molecular level, these effects were found to
be at least partially associated with β2AR/Akt/eNOS
pathway activation.
Endothelial dysfunction is known to play pivotal roles in
degenerative vascular disease. Restoration of endothelial
integrity is an important technique that can be used to
cure vascular disease. Since Asahara et al. [19] first culti-
vated EPCs, numerous experiments have shown that EPCs
mediated endothelial restoration in many processes, sug-
gesting that they may also be useful for treating vascular
injury. The term EPCs has been applied interchangeably
Fig. 2 Overexpression of β2AR in transfected EPCs. a β2AR mRNA levels were measured in non-Adv EPCs, Ad5/EGFP EPCs, and Ad5/β2AR EPCs
by using real-time polymerase chain reaction and normalized against β-actin (n = 5 per group). *P < 0.01 versus non-Adv EPCs or Ad5/EGFP EPCs.
NS not significant versus non-Adv-EPCs. b β2AR protein levels were significantly higher in the Ad5/β2AR EPC group than in the non-Adv EPC or
Ad5/EGFP-EPC group. *P < 0.01 versus non-Adv EPCs or Ad5/EGFP EPCs. NS not significant versus non-Adv-EPCs (n = 5 per group). Ad5 adenovirus
serotype 5, EGFP enhanced green fluorescent protein, EPC endothelial progenitor cell, β2AR β2 adrenergic receptor
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to a variety of cell populations by different investigators,
suggesting that EPCs are not a single type of cell popula-
tion. The definition of EPCs remains controversial. Many
studies have attempted to identify cell surface markers
that are unique to EPCs and to distinguish them from ma-
ture ECs and from myeloid-monocytic cells; however,
these attempts have met with little success. Broadly speak-
ing, two approaches to identify EPCs have predomi-
nated: (1) identification of cells bearing surface
markers that indicate both cellular naïveté and endo-
thelial origin and (2) inference of the presence of
endothelial precursors with a given cell population by
the identification of cells bearing mature endothelial
characteristics after a period of culture under angio-
genic conditions [20]. In our experiment, according to
the method of Hur et al. [14], isolated MNCs were
resuspended by using the EGM-2 BulletKit system.
After 5 to 7 days, attached cells were elongated and
had a spindle shape. The recognition of cell surface
antigen markers by flow cytometric analysis has con-
firmed the cells as early EPCs, consistent with the re-
sults of other studies [12, 21].
Fig. 3 β2AR gene transfer in EPCs upregulates cell proliferation, migration, and adhesion; NO production; and SDF-1/CXCR4 expression in vitro.
a Proliferation was measured in cultured EPCs by using CCK8 assays after 24 h of stimulation with FENO (10−8 M). The rate of proliferation in the
Ad5/β2AR EPC group was significantly higher than the rate in the non-Adv-EPC, non-Adv- EPC + FENO, or Ad5/EGFP-EPC groups (0.29 ± 0.05, 0.16
± 0.00, 0.24 ± 0.03, and 0.15 ± 0.01, respectively; *P < 0.01 versus non-Adv EPCs or Ad5/EGFP-EPCs, #P < 0.01 versus non-Adv-EPCs, non-Adv-EPCs +
FENO, or Ad5/EGFP-EPCs; n = 5 per group). b NO secretion was assayed in EPCs by using the nitrate reductase method after β2AR gene transfer.
The production of NO was significantly higher in the Ad5/β2AR-EPCs than in the non-Adv-EPCs, non-AdvEPCs + FENO, or Ad5/EGFP-EPCs (74.42 ±
8.68, 24.01 ± 2.68, 46.77 ± 4.08, and 24.24 ± 3.71, respectively; *P < 0.01 versus non-Adv-EPCs or Ad5/EGFP-EPCs, and #P < 0.01 versus non-Adv-EPCs,
non-Adv-EPCs + FENO, or Ad5/EGFP-EPCs; n = 5 per group). c and e Quantitative analyses (c) and representative photographs (e) showing the
migratory activity observed in EPCs (*P < 0.01 versus non-Adv-EPCs + FENO or Ad5/EGFP EPCs + FENO; n = 5 per group). d and f Quantitative
analyses (d) and representative photographs (f) of CM-DiI-labeled EPCs that adhered to human umbilical vein endothelial cells with or without
stimulation with TNF-α (1 μg/ml; *P < 0.01 versus non-Adv-EPCs + TNF-α or Ad5/EGFP-EPCs + TNF-α; n = 5 per group). g Overexpression of β2AR
increased the expression of SDF-1 and CXCR4 in EPCs. Representative photograph and quantification analysis for SDF-1 and CXCR4 expression in
EPCs (*P < 0.01 versus non-Adv EPCs without FENO activation, #P < 0.01 versus non-Adv-EPCs with FENO activation, and NS versus non-Adv-EPCs
without FENO activation, n = 5 per group). Ad5 adenovirus serotype 5, DiI-ac-LDL DiI-labeled acetylated low-density lipoprotein, EGFP enhanced
green fluorescent protein, EPC endothelial progenitor cell, FENO fenoterol, NO nitric oxide, NS not significant, SDF-1a stromal cell-derived factor 1a,
TNF-α tumor necrosis factor-α, β2AR β2 adrenergic receptor
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Maintenance of the normal number and function of
EPCs in the systemic circulation is now known to be an
important novel endogenous vascular repair factor. In ani-
mal and clinical research, transplanted EPCs can home to
impaired arteries, promoting re-endothelialization and re-
ducing neointima formation. Various molecules may be
involved in the process of EPC homing. EPCs and ECs
have previously been shown to express both β1ARs and
β2ARs [8, 9]. β2ARs are G protein-coupled receptors
that can induce cell proliferation and promote cell
survival in many tissues, and stimulation of endothe-
lial β2ARs has been shown to activate eNOS and re-
lease of NO in human umbilical vein endothelium
[22]. Previous studies have shown that EPCs and ECs
harvested from β2AR-knockout (β2AR-KO) mice are
impaired in their abilities to migrate and stimulate
network formation on Matrigel in vitro [8, 9]. More-
over, when β2AR-KO ECs and EPCs were injected
Fig. 4 β2AR gene transfer increases the re-endothelialization capacity of EPCs in vivo. Ad5/β2AR gene transfer contributed to the re-endothelialization
of injured carotid arteries. a Evans blue staining was used to identify segments of denuded endothelium immediately after nude mice were subjected
to wire-mediated carotid artery injury. Representative photograph shows an injured artery and a contralateral uninjured artery. b The transplantation of
EPCs that underwent Ad5/β2AR gene transfer resulted in a higher area of re-endothelialization than was observed in the PBS-injected and non-Adv
EPC transplantation group (n = 5) or the Ad5/EGFP EPC group (n = 5) (*P < 0.01 versus the PBS group, #P < 0.01 versus non-Adv-EPCs, or Ad5/EGFP-EPC
group). c Higher numbers of homed Ad5/β2AR EPCs than Ad5/EGFP EPCs were detected; n = 5 per group (*P < 0.01 versus Ad5/EGFP-EPC group).
d Homing was detected in β2AR-overexpressing EPCs by using CM-DiI-labeled EPC tracing and FITC BS-1 lectin co-staining in frozen tissue sections. To
demonstrate that the transfused EPCs that localized to the injured site were endothelial cells, null mice received FITC-labeled BS-1 lectin 30 min before
tissues were harvested. Ad5 adenovirus serotype 5, DiI-ac-LDL DiI-labeled acetylated low-density lipoprotein, EGFP enhanced green fluorescent protein,
EPC endothelial progenitor cell, FITC fluorescein isothiocyanate, PBS phosphate-buffered saline, β2AR β2 adrenergic receptor
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Fig. 5 (See legend on next page.)
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into ischemic hind limbs, no significant amelioration
of neovascularization was noted [8, 9]. However,
whether β2ARs mediate the capacity of EPCs to re-
endothelialize damaged arteries following an injury
has never previously been tested. Given the results
described in prior reports, we hypothesized that β2AR
overexpression in human EPCs would result in the
functional enhancement of EPCs in vitro and that
β2AR gene upregulation would contribute to the res-
toration of endothelial injury in vivo.
To address these assumptions, we first investigated the
effect of β2AR overexpression on the proliferation, migra-
tion, adhesion, and NO secretion of EPCs. We found that
when EPCs were stimulated with FENO, the rates of prolif-
eration and migration were significantly higher in EPCs that
overexpressed β2ARs, indicating that FENO-induced func-
tions were enhanced by β2AR overexpression in EPCs.
Furthermore, our results showed that TNF-α-induced
adhesion and NO secretion were enhanced by β2AR over-
expression in EPCs. Given the close association between
β2AR and EPC function, deeper insight into the contribu-
tion of β2AR expression in EPCs to accelerated re-
endothelialization may be of clinical importance for the
treatment of CVDs. We investigated the effect of infusing
cultured PB-derived EPCs in a previously described nude
mouse model of carotid artery injury. As shown in Fig. 4b,
β2AR overexpression in the infused EPCs resulted in a sig-
nificantly larger area of re-endothelialization, suggesting
that β2AR signaling might be an important molecular
mechanism that contributes to enhanced re-
endothelialization by EPCs. Notably, the SDF-1α/CXCR4
interaction plays an important role in the regulation of a
variety of cellular functions, including cell migration, prolif-
eration, survival, and angiogenesis. Previous studies have
demonstrated that the SDF-1a/CXCR4 axis is crucial for
the therapeutic integrity of EPCs and their ability to home
to injured vessels. For example, investigators showed that
SDF-1a was involved in ischemia-mediated mobilization
and homing in EPCs after vascular injury [18]. It has also
been reported that CXCR4 expression restored the
functions of EPCs in hypertensive patients [23]. Our data
showed that stimulation with β2AR promoted EPC func-
tion and significantly increased SDF-1a and CXCR4 expres-
sion in cultured EPCs, especially in EPCs that
overexpressed β2AR. These data collectively suggest that
β2AR is an important potential therapeutic target and that
β2AR-mediated EPC functions are dependent, at least in
part, on the production of SDF-1a/CXCR4 and may other-
wise be equal to the SDF/CXCR4 axis in the biology of
EPCs. Therefore, our results indicate that transplantation of
EPCs that have enhanced β2AR expression could be used
as a novel therapy for treating vascular endothelial injuries.
In regard to how β2AR gene transfer modulates re-
endothelialization, several lines of evidence have shown that
activation of β2ARs promoted the proliferation and survival
of cardiac progenitor cells in association with increased
eNOS phosphorylation [24, 25]. Akt, a multifunctional
regulator of cell survival, is a downstream effector of
phosphatidylinositol-3 kinase (PI3K). It is widely accepted
that activating Akt phosphorylation stimulates eNOS phos-
phorylation at Ser1177 and increases endothelial NO pro-
duction, which is involved in the mobilization of stem and
progenitor cells [26]. Our current data demonstrate that
this signal paradigm also exists in EPCs because β2AR
stimulation increased the phosphorylation of Akt and
eNOS, which is consistent with increased EPC proliferation,
migration, and adhesion function in vitro and with acceler-
ated re-endothelialization in vivo. These cellular effects are
blocked by β2AR/Akt/eNOS inhibition. Furthermore, we
upregulated the expression of β2AR via Ad5/β2AR gene
transfer and found that the increased re-endothelialization
capacity that was induced in the cultured EPCs that overex-
pressed β2AR was blocked by the β2AR inhibitor ICI111,
181; the Akt inhibitor LY294002; and the eNOS inhibitor
L-NAME. These data strongly support the hypothesis that
β2AR plays a crucial role in the regulation of vascular re-
pairs by circulating EPCs. We believe that this study is also
the first to provide data indicating that mechanisms involv-
ing β2AR signaling underlie the functions of EPCs in vitro
and their capacity to re-endothelialize injuries in vivo.
(See figure on previous page.)
Fig. 5 The β2AR/Akt/eNOS pathway improves EPC function in vitro and the endothelial repair capacity of EPCs in vivo. a Representative
photograph and quantification analysis of Akt phosphorylation in EPCs (*P < 0.01 versus Ad5/EGFP-EPCs with FENO activation, #P < 0.05 versus
Ad5/β2AR-EPCs with FENO activation, and NS versus Ad5/EGFP-EPCs; n = 5 per group). b Representative photograph and quantification analysis
of eNOS phosphorylation in EPCs (*P < 0.01 versus Ad5/EGFP-EPCs with FENO activation, #P < 0.01 versus Ad5/β2AR-EPCs with FENO activation,
and NS versus Ad5/EGFP-EPCs; n = 5 per group). c Quantification analysis of migration (*P < 0.01 versus Ad5/EGFP-EPCs with FENO activation and
#P < 0.01 versus Ad5/β2AR-EPCs with FENO activation; n = 5 per group). d Quantification analysis of adhesion (*P < 0.05 versus Ad5/EGFP-EPCs
with FENO activation and #P < 0.05 versus Ad5/β2AR-EPCs with FENO activation; n = 5 per group). e Quantification analysis of proliferation (*P <
0.05 versus Ad5/EGFP-EPCs with FENO activation and #P < 0.05 versus Ad5/β2AR-EPCs with FENO activation; n = 5 per group). f Quantification
analysis of NO production (*P < 0.05 versus Ad5/EGFP-EPCs with FENO activation and #P < 0.05 versus Ad5/β2AR-EPCs with FENO activation; n = 5
per group). g The re-endothelialized area at day 3 after carotid injury in nude mice with transplantation of Ad5/β2AR-EPCs that were pre-treated with
β2AR or Akt or eNOS inhibitors (*P < 0.01 versus Ad5/β2AR-EPCs; n = 5 per group). Ad5 adenovirus serotype 5, EGFP enhanced green fluorescent
protein, eNOS endothelial nitric oxide synthase, EPC endothelial progenitor cell, FENO fenoterol, NO nitric oxide, NS not significant, β2AR
β2 adrenergic receptor
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The present study has some limitations. First, although
we used a β2AR inhibitor to explore the important func-
tions of EPCs in the vitro and in vivo experiments, we did
not focus on exploring the functional impairments that
were observed in the β2AR-KO EPCs during homing to
impaired arteries. Second, β2AR gene transfer results in ac-
celerated re-endothelialization after vascular injury, but the
adenovirus-mediated β2AR gene overexpression should be
verified to determine its clinical safety. Finally, we used a
relatively simple model in nude mice to demonstrate that
β2AR gene transfer resulted in EPCs with enhanced repair
capacities. Whether the β2AR/Akt/eNOS signaling pathway
contributes more or less to EPCs to mediate endothelial re-
pair relative to the contributions of other signaling path-
ways needs to be further investigated.
Conclusions
Our study is the first to provide direct evidence that β2AR
expression in EPCs is an important molecular target for
therapeutic studies and that β2AR activation may be
responsible for accelerated EPCs homing during injury.
More importantly, our study demonstrates that overex-
pressing the β2AR gene in EPCs results in rapid re-
endothelialization and largely improved post-injury vascular
repairs and that these processes are mediated by the β2AR/
Akt/eNOS signaling pathway. Stem cell therapies have
shown great potential as strategies aimed at increasing the
efficiency of vascular regeneration; therefore, β2AR gene
may become a novel therapeutic molecular target in clinical
studies aimed at improving cardiovascular care. These sci-
entific questions deserve further investigation.
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